Uni-Bio Science (HK690) Appoints CEO, Non-Executive Director and Independent Non-executive Director Leveraging on Deep Industry Knowledge to Garner New Impetus

HONG KONG, April 9, 2019 /PRNewswire/ -- A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (the "Company", together with its subsidiaries, the "Group"; Stock code: 0690.HK), is pleased to announce the appointment of Mr. Zhao Zhi Gang as the CEO, Mr. Ma Qing Shan as independent non-executive director and Mr. Tony Yau as non-executive director of the Group, effective on 8 April 2019.


The appointment of Mr. Zhao, Mr. Ma and Mr. Yau are of profound significance for the Group. Mr. Zhao attained his bachelor's degree in Economics from Peking University in 1983, and furthered his study for a master's degree in Professional Accounting from the University of Hartford, Connecticut, United States. Mr. Zhao is a U.S. certified public accountant and a fellow of the American Institute of Certified Public Accounts. Prior to his appointment, Mr. Zhao has garnered profound expertise in finance and management for over 20 years in various publicly listed companies and PricewaterhouseCoopers in the U.S. and in PRC., and offered advice to numerous listed companies on M&A and business spinoff projects, and showcasing his outstanding managerial capabilities from then. He has provided services for the pharmaceutical industry for many years, including Kingmed Center for Clinical Laboratories in Guangzhou and the U.S.-listed Simcere Pharmaceutical Group, where he gathered deep industry insight. The Group believes that the joining of Mr. Zhao will help optimize the cost-control structure and enhance operating efficiency for the Group.


Mr. Ma attained two bachelor's degrees from Peking University, majoring in Finance at Guanghua School of Management and Electronic Commerce at School of Electronics Engineering and Computer Science. He is holding the qualification of the Chartered Financial Analyst (CFA). He also participated in the Insead EMBA project held by Tsinghua University. Prior to his appointment, Mr. Ma has provided services at various consulting firms and practiced management for over 16 years, including provision of management consulting services for 15 Fortune 500 companies and a number of listed public companies and fast-growing enterprises,    and also once serving as consulting director of KPMG Advisory (China) Limited and Accenture (China) Co., Ltd.. Leveraging on his years of practical experience in data management, corporate KPI management, business optimization and digitization for companies, the Group believes that Mr. Ma's joining will help better integrate the Group's current business with information technologies, and improve resources allocation for the Group.


Mr. Yau attained his bachelor's degree with first class honours in Accountancy from The Hong Kong Polytechnic University. He is a certified public accountant (CPA) of the Hong Kong Institute of Certified public Accountants. Mr. Yau has deep insight in corporate management and accumulated over 20 years of experience from the capital market and investment banks. He offered consultancy services to many large-scale and recognizable IPO and M&A projects. He is currently the Chief Executive Officer and a director of Futec International Holdings Limited and HeungKong Financial Group Limited. Prior to that, he was a Managing Director of Global Investment Banking of Deutsche Bank and had spent over 11 years leading the consumer sector business origination and execution in Asia. From August 2000 to May 2006, Mr. Yau was the vice president of the investment banking department of BNP Paribas Capital (Asia Pacific) Limited. The Group believes that Mr. Yau's remarkable experience and executive capability will lead the Group to higher achievements.


Commenting on their appointment, Mr. Kingsley Leung, Chairman of and Executive Director of Uni-Bio Science Group Limited said, "In the past 5 years, Mr. Zhao has been our independent non-executive director, and obtained deep understanding of our business, values and prospect, he decided to join our senior management team because he strongly believes in the Uni-Bio story. I am also equally excited to have Mr. Ma and Mr. Yau join our team, their expertise and past experience are all top tier, the profile of our board is extremely unique and exceptionally capable for a small cap company in Hong Kong."


Mr. Leung continued: "Given the fast changing biopharmaceutical market in China, the Group has always welcomed changes to better adapt to the competitive landscape. For that reason, the Group has recently completed a restructuring to move from the past divisional organizational structure to functional organizational structure. The new structure enables better control, less bureaucracy, and higher efficiency for the organization. Currently we have formed 8 BUs to cover key activities across the value chain. We also proposed better accountability for each BU head in order to drive results more clearly. Amid the fast developing stage where numerous innovative biologic drugs will soon be launched, we aim to reduce another 20% of cost for the Group in the coming year. In addition, we aim to increase the efficacy of capital expenditure to underpin operating capabilities. In 2018, we carried out the above transformations and have reduced our general administrative expenses by 16.6%. We believe we can continue to leverage on this experience in 2019 and further reduce cost to an optimal level without impacting our operations."


- END -


About Uni-Bio Science Group Limited


Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The research and development center is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with NMPA requirements. The Group also has two GMP manufacturing bases in Beijing and Shenzhen. The Group is focused on the development of novel treatments and innovative drugs addressing the therapeutic areas of diabetes, ophthalmology and dermatology.


Uni-Bio Science Group Limited was listed on the Main Board of the Hong Kong Stock Exchange on November 12, 2001. Stock code: 0690.


For further information, please contact:


Jacob Zhang   Phone: +86 10 5914 0747 Email: jacob.zhang@uni-bioscience.com

Tags:
Look out for further updates on our Facebook fan page!

Related Articles

  • 【人才管理】欣賞員工唔一定要用錢嘅! 專家建議5個方法一樣得

    疫情下老闆當然撐得辛苦,但員工也正在拼命為公司付出。一間企業成功與否,除了在於老闆的領導能力和視野,留住人才也是一大關鍵......

  • 【人才管理】真金助員工渡難關!Facebook宣布向員工派發獎金$7700元

    新冠肺炎擴散全球,各國的經濟受到不同程度的打擊。企業面減虧蝕、停業甚至倒閉風險,打工仔則面臨減薪、失業的壓力。根據美國有線電視新聞網(CNN) 報導,科技巨頭Facebook宣布向4萬5千名員工發放1,000美元的補助金(約7,766港元)。

  • 【企業管理】流動網絡普及 企業貪快貪方便蒙受損失

    【經濟日報專訊】流動網絡普及,人人一機在手即可在網上四通八達。可是,這亦令流動安全防護變得複雜,讓黑客及不法分子有機可乘。

  • 【新冠肺炎】員工怕「中招」拒上班 管理層無法說服結果......

    疫情嚴重影響到各大企業的運作,如果業務性質許可,企業能安排員工在家工作(Work From Home)當然最好,但是部分行業難以實行......

  • 【新冠肺炎】公務員逐步復工 專家︰企業是否跟隨考慮幾個因素

    【經濟日報專訊】本港由上月23日出現首宗新冠肺炎(武漢肺炎)輸入個案,至昨累計達93宗,接近破百關口,而昨2宗確診個案,均涉北角佛堂群組。而下周就踏入3月,本港疫情是否有回落迹象?社會是否應恢復正常工作安排?

  • 【新冠肺炎】確診新冠肺炎前有症狀仍上班 網民:社畜病毒威力太強大

    截至今早10時半,最新香港新冠肺炎(武漢肺炎)的確診個案已上升至68宗,2人死亡,仍有111宗個案仍需住院檢查。雖然鑑於疫情嚴......

  • 【網民職場Talk】下屬奉旨幫上司執手尾?打工仔列慘痛經歷

    打工仔工作繁忙,加上工時長,每天與同事相處的時間比家人、伴侶、朋友還要多,如果不幸遇上能力不高的上司,更會為工作添煩添亂。一個體貼下屬、表現出眾的上司,可謂可遇不可求,當你在職場打滾多年後,或許會發現職位高低往往與能力的高低不成正比。有網民向社交媒體專頁《奴工處》投稿,分享為人下屬的辛酸。

  • 【職場熱話】18區最痛苦的返工地點!觀塘熱到變蒸爐?

    香港的打工仔的確可憐,朝朝起身迫巴士、港鐵上班,人多車又疏,最弊近幾日天氣熱到令人中暑,未回到公司已經大汗疊細汗,成身臭味。一早起身壓力已經爆煲,有網友忍不住要在討論區開Post,讓大家一起「嚴選最地獄返工地點」,不知道哪區是你的心水呢?

  • 【網民職場Talk】大學Third Hon畢業 連累失面試機會?

    大學生近日陸續完成課程,開始踏上求職之路。若在大學取得一級榮譽(First Hon),可能會為CV加分,但在取得三級榮譽(Third Hon)的話,又會否影響僱主聘請意欲呢?有Third Hon畢業生遲遲未找到工作,在社交專頁《奴工處》投稿,了解Third Hon是否真的影響求職。

  • 【政府工略】政府統計處請統計助理 月薪$20,035 點先做到?

    政府統計處最近招聘統計助理,只要你持有香港統計學會頒發的統計學普通證書,或者擁有以下學歷即可申請,月薪$20,035,以非公務員合約條款受聘,為期約6月12個月。